20 March 2015
ONLY FOR HEALTHCARE PROFESSIONALS
March 13-14, NovaMedica participated in the annual conference “The 14th All-Russian Ophthalmologist School 2015” near Moscow. The event welcomed more than 200 medical specialist from all over Russia. The opinion leaders’s reports and presentations covered various issues of therapeutical and surgical ophtalmology.
The conference participants met Professor Maria A. Kovalevskaya from Voronezh State Medical Academy of N.N. Burdenko who presented a report on modern aspects of eye infection antibiotic therapy prepared under support of NovaMedica.
Professor Kovalevskaya, a recognized opinion leader in ophthalmology, introduced the most effective treaments to the ophtalmological community, particularly, two block-buster products in NovaMedica’s portfolio originated by SIFI (Italy): Nettacin and Colbiocin. The report provoked heated discussions on the urgent issues of antibiotic therapy including the Italian products on the Russian market.
NovaMedica’s exhibition stand with the whole ophalmological portfolio of the company attracted a lot of attention from the professional audience. NovaMedica’s ambition to become one of the leading players on the Russian ophtalmological market was sincerely approved by the academic and practicing community.
Reference information:
NovaMedica is a Russian pharmaceutical company established in 2012 by DRI Holdings Limited, a portfolio company of Domain Associates LLC, a venture capital firm with an exclusive focus on investing in life science companies, and Russian investment corporation RUSNANO, which initiatives to promote the Russian government’s policy of fostering hi-tech industries.
NovaMedica was formed to provide the development, marketing and operational capabilities needed to commercialize highly innovative next-generation products from the collaboration in Russia and the CIS.
The company’s strategy is aimed at localizing production of a wide range of new medicines and technologies for the Russian market, including establishing screening and registration operations and innovative GMP-standard manufacturing facilities.
Please visit www.novamedica.com for more detailed information.
PrintMerry Christmas and Happy New Year!
28 December 2024
NovaMedica team in the TOP 100 INFLUENTIAL PEOPLE IN THE PHARMACEUTICAL BUSINESS 2024
28 November 2024
05 November 2024
Enhancing spectroscopy analysis with machine learning
03 February 2025
The production of new Russian “super antibiotic” to begin in Novosibirsk
03 February 2025
A Russian company has started producing 4 veterinary vaccines
31 January 2025
The government held its first meeting on the “New technologies for preserving health” project
31 January 2025